Fuchs endothelial corneal dystrophy Market Analysis: Epidemiology Insights, Therapies, Companies, by DelveInsight | Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon

The total Fuchs Endothelial Corneal Dystrophy (FECD) market size of in the 7MM in 2023 was approximately ~USD 858 million, this is anticipated to grow by 2034.
Emerging therapies for Fuchs endothelial corneal dystrophy, including Ripasudil (K-321), TTHX 1114, and others, are anticipated to drive growth in the Fuchs endothelial corneal dystrophy market in the coming years.

DelveInsight has introduced a new report, "Fuchs Endothelial Corneal Dystrophy - Market Insights, Epidemiology, and Market Forecast-2034", which provides a comprehensive overview of the condition, its historical and projected epidemiology, along with market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover about the Fuchs endothelial corneal dystrophy market report @ https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Fuchs endothelial corneal dystrophy Market Report:

*
In 2023, the Fuchs Endothelial Corneal Dystrophy (FECD) market across the seven major markets (7MM) was valued at about USD 858 million, with steady growth anticipated through 2034. The United States held the largest share, contributing nearly USD 394 million, while among the EU4 (Germany, Italy, France, Spain) and the UK, Germany led with approximately USD 88 million, followed by Italy at USD 67 million. Spain represented the smallest share at around USD 50 million.

*
DelveInsight estimates that the US accounted for nearly 35% of diagnosed prevalent cases of FECD in 2023, making it the largest contributor among the 7MM. By contrast, Spain represented the smallest share, with around 7% of diagnosed cases. In the EU4 and the UK, there were about 9.2 million diagnosed prevalent cases in 2022, with the 50-59 age group showing the highest prevalence-approximately 2.7 million cases in 2023. These numbers are expected to rise steadily during 2020-2034.

*
The FECD treatment market is projected to expand further with the introduction of novel therapies such as Ripasudil (K-321), TTHX1114/NM141, and others. Design Therapeutics is advancing DT-168, a GeneTAC Registered small-molecule eye drop targeting the mutant TCF4 gene linked to FECD. Following encouraging Phase 1 results in healthy volunteers, a Phase 2 biomarker trial in FECD patients is expected in the second half of 2025. If successful, DT-168 could become the first disease-modifying therapy for FECD.

*
Additionally, a corneal cell therapy involving implantation of cultured human endothelial cells received clinical use approval in Japan in early 2024. This therapy is also under investigation in the United States, with potential FDA approval projected for 2026-2027, depending on clinical trial outcomes.

*
Key companies working to improve the FECD treatment landscape include Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon, and others. Promising pipeline therapies include Ripasudil (K-321), TTHX1114, and more.

Fuchs endothelial corneal dystrophy Overview

Fuchs Endothelial Corneal Dystrophy (FECD) is a progressive, inherited disorder affecting the corneal endothelium. It is characterized by corneal edema, the presence of guttae, reduced visual acuity, and can ultimately lead to corneal blindness. The condition is more commonly observed in women and shows regional variations across the seven major markets (7MM). FECD is primarily associated with genetic mutations, including those in COL8A2, SLC4A11, TCF4, and ZEB1, which contribute to its development.

Fuchs endothelial corneal dystrophy Market Outlook

The management of Fuchs Endothelial Corneal Dystrophy (FECD) encompasses a variety of treatment strategies. Primary approaches involve the use of hyperosmotic sodium chloride, corticosteroids, and other therapies as needed.

At present, the standard of care-particularly hyperosmotic sodium chloride and steroids-remains a key contributor to revenue within the FECD treatment market.

Discover how the Fuchs endothelial corneal dystrophy market is rising in the coming years @ https://www.delveinsight.com/sample-request/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Fuchs endothelial corneal dystrophy Emerging Drugs

*
Ripasudil (K-321): Kowa Pharmaceuticals

*
TTHX 1114: Trefoil Therapeutics

Scope of the Fuchs endothelial corneal dystrophy Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Fuchs endothelial corneal dystrophy Companies: Kowa Pharmaceuticals, Trefoil Therapeutics, Alcon, and others

*
Key Fuchs endothelial corneal dystrophy Therapies: Ripasudil (K-321), TTHX 1114, and others

*
Fuchs endothelial corneal dystrophy Therapeutic Assessment: Fuchs endothelial corneal dystrophy current marketed and Fuchs endothelial corneal dystrophy emerging therapies

*
Fuchs endothelial corneal dystrophy Market Dynamics: Fuchs endothelial corneal dystrophy market drivers and Fuchs endothelial corneal dystrophy market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Fuchs endothelial corneal dystrophy Unmet Needs, KOL's views, Analyst's views, Fuchs endothelial corneal dystrophy Market Access and Reimbursement

To know what's more in our Fuchs endothelial corneal dystrophy report, visit https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Key benefits of the Fuchs endothelial corneal dystrophy Market Report:

*
Fuchs endothelial corneal dystrophy market report covers a descriptive overview and comprehensive insight of the Fuchs endothelial corneal dystrophy Epidemiology and Fuchs endothelial corneal dystrophy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).

*
The Fuchs endothelial corneal dystrophy market report provides insights into the current and emerging therapies.

*
The Fuchs endothelial corneal dystrophy market report provides a global historical and forecasted market covering drug outreach in 7MM.

*
The Fuchs endothelial corneal dystrophy market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Fuchs endothelial corneal dystrophy market.

Got queries? Click here to know more about the Fuchs endothelial corneal dystrophy market Landscape [https://www.delveinsight.com/sample-request/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Fuchs endothelial corneal dystrophy Patient Share (%) Overview at a Glance

5. Fuchs endothelial corneal dystrophy Market Overview at a Glance

6. Fuchs endothelial corneal dystrophy Disease Background and Overview

7. Fuchs endothelial corneal dystrophy Epidemiology and Patient Population

8. Country-Specific Patient Population of Fuchs endothelial corneal dystrophy

9. Fuchs endothelial corneal dystrophy Current Treatment and Medical Practices

10. Unmet Needs

11. Fuchs endothelial corneal dystrophy Emerging Therapies

12. Fuchs endothelial corneal dystrophy Market Outlook

13. Country-Wise Fuchs endothelial corneal dystrophy Market Analysis (2020-2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Fuchs endothelial corneal dystrophy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Click here to read more about Fuchs endothelial corneal dystrophy Market Outlook 2034 [https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Related Reports:

Fuchs endothelial corneal dystrophy Pipeline Insights, DelveInsight

"Fuchs endothelial corneal dystrophy Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Fuchs endothelial corneal dystrophy market. A detailed picture of the Fuchs endothelial corneal dystrophy pipeline landscape is provided, which includes the disease overview and Fuchs endothelial corneal dystrophy treatment guidelines.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=fuchs-endothelial-corneal-dystrophy-market-analysis-epidemiology-insights-therapies-companies-by-delveinsight-kowa-pharmaceuticals-trefoil-therapeutics-alcon]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.